You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKesson
Johnson and Johnson
Colorcon
Dow

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021323


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 021323 describes LEXAPRO, which is a drug marketed by Allergan and is included in two NDAs. It is available from three suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the LEXAPRO profile page.

The generic ingredient in LEXAPRO is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.
Summary for 021323
Tradename:LEXAPRO
Applicant:Allergan
Ingredient:escitalopram oxalate
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 021323
Mechanism of ActionSerotonin Uptake Inhibitors
Suppliers and Packaging for NDA: 021323
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LEXAPRO escitalopram oxalate TABLET;ORAL 021323 NDA Allergan, Inc. 0456-2005 0456-2005-01 100 TABLET, FILM COATED in 1 BOTTLE (0456-2005-01)
LEXAPRO escitalopram oxalate TABLET;ORAL 021323 NDA Allergan, Inc. 0456-2010 0456-2010-01 100 TABLET, FILM COATED in 1 BOTTLE (0456-2010-01)
Paragraph IV (Patent) Challenges for 021323
Tradename Dosage Ingredient NDA Submissiondate
LEXAPRO TABLET;ORAL escitalopram oxalate 021323 2005-08-17
LEXAPRO TABLET;ORAL escitalopram oxalate 021323 2005-03-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Aug 14, 2002TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Feb 12, 2023Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:Feb 12, 2023Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Aug 14, 2002TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Feb 12, 2023Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021323

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan LEXAPRO escitalopram oxalate TABLET;ORAL 021323-003 Aug 14, 2002   Start Trial   Start Trial
Allergan LEXAPRO escitalopram oxalate TABLET;ORAL 021323-001 Aug 14, 2002   Start Trial   Start Trial
Allergan LEXAPRO escitalopram oxalate TABLET;ORAL 021323-002 Aug 14, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKesson
Johnson and Johnson
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.